Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aeterna Zentaris Inc (AEZS.TO)

Aeterna Zentaris Inc (AEZS.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,251
  • Shares Outstanding, K 4,856
  • Annual Sales, $ 5,260 K
  • Annual Income, $ -8,368 K
  • 60-Month Beta 1.74
  • Price/Sales 4.40
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade AEZS.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -2.66
  • Most Recent Earnings -0.70 on 11/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 1,237.498 on 08/11/99
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.26
  • Number of Estimates 1
  • High Estimate -1.26
  • Low Estimate -1.26
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -68.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.66 +9.01%
on 11/18/22
5.31 -4.33%
on 11/08/22
-0.38 (-6.96%)
since 11/07/22
3-Month
4.66 +9.01%
on 11/18/22
6.48 -21.60%
on 09/13/22
-0.57 (-10.09%)
since 09/07/22
52-Week
4.66 +9.01%
on 11/18/22
16.50 -69.21%
on 12/24/21
-9.42 (-64.97%)
since 12/07/21

Most Recent Stories

More News
Aeterna Zentaris: Q3 Earnings Snapshot

Aeterna Zentaris: Q3 Earnings Snapshot

AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline ...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)
Stocks in play: Aeterna Zentaris Inc.

Today announced its Autoimmunity Modifying Biologicals program has achieved pre-clinical proof-of-concept ...

AEZS.TO : 5.08 (-2.31%)
Stocks in play: Aeterna Zentaris Inc

Announced Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the JMP Securities ...

AEZS.TO : 5.08 (-2.31%)
Stocks in play: Aeterna Zentaris Inc.

Announced that Ghryvelin™ (macimorelin), the first oral test approved for diagnosing Growth Hormone ...

AEZS.TO : 5.08 (-2.31%)
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...

AEZS : 3.69 (-1.91%)
AEZS.TO : 5.08 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 5.08
1st Resistance Point 5.08
Last Price 5.08
1st Support Level 5.08
2nd Support Level 5.08
3rd Support Level 5.08

See More

52-Week High 16.50
Fibonacci 61.8% 11.98
Fibonacci 50% 10.58
Fibonacci 38.2% 9.18
Last Price 5.08
52-Week Low 4.66

See More

Business Summary

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar